Burzynski Research Institute - Stock

Burzynski Research Institute Debt 2024

Burzynski Research Institute Debt

-0 USD

Ticker

BZYR

ISIN

US1231591058

WKN

A0CA3Q

In 2024, Burzynski Research Institute's total debt was -0 USD, a -61.24% change from the -0 USD total debt recorded in the previous year.

Burzynski Research Institute Aktienanalyse

What does Burzynski Research Institute do?

The Burzynski Research Institute Inc is a company based in Houston, Texas, that specializes in the development of cancer treatments. The company was founded in 1976 by Polish physician Stanislaw R. Burzynski, who began his first research on tumor cells. Burzynski made a promising discovery: He identified a group of chemical compounds that he referred to as "Antineoplastons" and described them as effective cancer-fighting agents. One of his key hypotheses was that cancer cells in the body develop due to a malfunction in the normal body's mechanism for combating cancer cells. He therefore developed a therapy that aims to support and enhance this mechanism in the body that normally fights cancer. Burzynski founded the Burzynski Research Institute to further develop his research and therapy. The company's business model is based on the clinical development, patenting, and marketing of cancer treatment methods that rely on the use of Antineoplastons as a central active ingredient. An essential part of the institute's work is collaborating with regulatory authorities such as the US Food and Drug Administration (FDA) to obtain approval for these therapies. The company has obtained several approvals for clinical trials with its cancer treatment technology, including an approval in 2003 for a clinical trial on children with brainstem cancer. The Burzynski Research Institute specializes in various types of cancer treatment, including brain tumors, breast cancer, prostate cancer, and lung cancer. The company also utilizes several different types of Antineoplastons, including phenylacetate, phenylbutyrate, and O-(chloroacetyl)carboxy-phenylglycine. In addition to cancer therapy, the institute also develops other medical products. For example, the institute offers a product called "Emu oil," which is a natural pain-relieving and anti-inflammatory oil. These products are mostly sold directly to patients and are typically not the main source of revenue for the company. The Burzynski Research Institute is not without controversy. There are critics who argue that the company lacks sufficient scientific evidence to prove the effectiveness of their cancer treatment methods. Others have criticized the high prices charged by the company for their treatments. Despite these criticisms, the Burzynski Research Institute has continued its work and further developed its cancer treatment technology, with the aim of finding new and effective ways to combat cancer. The company has also published several books and videos to raise awareness of its work and goals. Overall, the company can be considered a leading, albeit controversial, player in the field of cancer research and therapy. Its products and treatment approaches offer hope and solutions for many cancer patients, but there are still many questions and challenges to be addressed in this important area of medical research. Burzynski Research Institute ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Burzynski Research Institute's Debt Structure

Burzynski Research Institute's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Burzynski Research Institute's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Burzynski Research Institute’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Burzynski Research Institute’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Burzynski Research Institute Stock

What is the debt of Burzynski Research Institute this year?

Burzynski Research Institute has a debt level of -0 USD this year.

What was the debt of Burzynski Research Institute compared to the previous year?

The debt of Burzynski Research Institute has increased by -61.24% compared to the previous year dropped.

What are the consequences of high debt for investors in Burzynski Research Institute?

High debt can pose a risk for investors of Burzynski Research Institute, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Burzynski Research Institute?

Low debt means that Burzynski Research Institute has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Burzynski Research Institute affect the company?

An increase in debt of Burzynski Research Institute can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Burzynski Research Institute affect the company?

A reduction in debt of Burzynski Research Institute can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Burzynski Research Institute?

Some factors that can influence the debt of Burzynski Research Institute include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Burzynski Research Institute so important for investors?

The debts of Burzynski Research Institute are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Burzynski Research Institute take to change the debt?

To change the debt, Burzynski Research Institute can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Burzynski Research Institute pay?

Over the past 12 months, Burzynski Research Institute paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Burzynski Research Institute is expected to pay a dividend of 0 USD.

What is the dividend yield of Burzynski Research Institute?

The current dividend yield of Burzynski Research Institute is .

When does Burzynski Research Institute pay dividends?

Burzynski Research Institute pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Burzynski Research Institute?

Burzynski Research Institute paid dividends every year for the past 0 years.

What is the dividend of Burzynski Research Institute?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Burzynski Research Institute located?

Burzynski Research Institute is assigned to the 'Health' sector.

Wann musste ich die Aktien von Burzynski Research Institute kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Burzynski Research Institute from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Burzynski Research Institute pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Burzynski Research Institute in the year 2023?

In the year 2023, Burzynski Research Institute distributed 0 USD as dividends.

In which currency does Burzynski Research Institute pay out the dividend?

The dividends of Burzynski Research Institute are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Burzynski Research Institute

Our stock analysis for Burzynski Research Institute Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Burzynski Research Institute Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.